BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...
Dr. Greg Hundley: Yes, Peder, let's go. Dr. Peder Myhre: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback